Hepatitis b cure latest news 2017

As of 2017, there is no cure for hepatitis B, but there are several treatments available that can help manage the disease and reduce the risk of complications. Here are some of the latest developments and news related to hepatitis B treatment:

New treatments:

  1. Nucleos(t)ide analogues: These are oral medications that are commonly used to treat chronic hepatitis B. In 2017, the FDA approved two new nucleos(t)ide analogues: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
  2. Pegylated interferon: This is a type of interferon that is given by injection and is used to treat chronic hepatitis B. In 2017, the FDA approved a new formulation of pegylated interferon called peginterferon lambda-1a.
  3. Elbasvir-grazoprevir: This is a new combination therapy that was approved in 2017 for the treatment of chronic hepatitis B. It is a pill that is taken once a day and is used in combination with other medications.

Breakthroughs:

  1. Hepatitis B vaccine: In 2017, researchers made a breakthrough in the development of a new hepatitis B vaccine that is more effective and longer-lasting than current vaccines.
  2. Gene therapy: Scientists have been exploring the use of gene therapy to treat hepatitis B. In 2017, a study published in the journal Nature Medicine reported promising results using gene therapy to cure hepatitis B in mice.
  3. Immunotherapy: Researchers have been investigating the use of immunotherapy to treat hepatitis B. In 2017, a study published in the journal Science Translational Medicine reported that immunotherapy can stimulate the immune system to fight off hepatitis B.

News and updates:

  1. WHO launches new hepatitis B treatment guidelines: In 2017, the World Health Organization (WHO) launched new guidelines for the treatment of hepatitis B. The guidelines recommend the use of antiviral medications for people with chronic hepatitis B who are at high risk of developing liver cancer or cirrhosis.
  2. Hepatitis B awareness campaign: In 2017, the Centers for Disease Control and Prevention (CDC) launched a new awareness campaign to raise awareness about hepatitis B and the importance of getting vaccinated.
  3. Research funding: In 2017, the National Institutes of Health (NIH) announced a new funding initiative to support research on hepatitis B and other liver diseases.

Key statistics:

  1. Global prevalence: According to the WHO, an estimated 257 million people worldwide are living with chronic hepatitis B.
  2. Mortality rate: The WHO estimates that hepatitis B causes approximately 887,000 deaths worldwide each year.
  3. Vaccination rates: According to the CDC, only about 2% of adults in the United States have been vaccinated against hepatitis B.

Overall, while there is no cure for hepatitis B, there are several effective treatments available, and researchers are continuing to explore new and innovative approaches to managing the disease.